Microsoft word - n90909 aaahc iqi awards 2009 news release.doc
312-558-1770, ext. 153
Programs to Combat Depression in College Students, Reduce Inappropriate Use of
Antibiotics Win Innovations in Quality Improvement Awards
Awards Presented by the AAAHC Institute for Quality Improvement
Skokie, Ill. [Sept. 9, 2009] — A national initiative to identify and treat college students who
suffer from depression, and a program that reduces the potential misuse of potent broad spectrum
antibiotics are the winners of the 2009 Innovations in Quality Improvement Awards from the
AAAHC Institute for Quality Improvement (AAAHC Institute), a not-for-profit subsidiary of the
Accreditation Association for Ambulatory Health Care (AAAHC/Accreditation Association).
The winners will present their studies and receive their awards at the AAAHC Institute’s
9th Annual National Educational Forum
for Ambulatory Health Care, Dec. 5 – 6, in Las Vegas.
For more information or to register, visit www.aaahciqi.org and click on “National Educational
Depression in College Students
“Unrecognized and untreated depression is currently the most common serious public
health problem in college students,” said Henry Chung, M.D., associate vice president of student
health, New York University, who first developed the program and will accept the award on
behalf of the National College Depression Partnership (NCDP). NYU piloted and is the national
According to a survey conducted by the American College Health Association, the
number of college students who reported receiving a diagnosis of clinical depression increased
from 10 percent in 2000 to 16 percent in 2005. In 2008, 11 percent of students were diagnosed
with depression, but the survey also found high rates of hopeless feelings (47 percent), feeling
overwhelmed (87 percent), feeling overwhelming anxiety (49 percent), feeling so depressed that
it was difficult to function (31 percent) and feeling overwhelming anger (39 percent).
In a population of nearly 18 million students, as many as 2.35 million may experience
significant depression during their college years.
“The impact of depression on college students is substantial. It negatively affects
learning, success in school and student retention, yet most students go undiagnosed and
untreated,” Chung said. A 2005 survey of college counseling directors found that only 17.5
percent of 154 students who committed suicide had been treated for depression, he said.
For the NCDP program, more than 80,000 students have been screened since June 2008,
out of a total of 200,000 enrolled students at 20 participating schools.* Of students who were
identified as clinically depressed, 91.8 percent began treatment within four weeks. At 12 weeks,
nearly half (47.8 percent) reported improved functioning.
For more information, visit www.nyu.edu/ncdp.
Reducing Misuse of Potent Antibiotics
The Delaware Surgery Center, Dover, will receive the other Innovations in Quality
Improvement Award for a program to reduce unnecessary use of the potent antibiotics
ciprofloxacin (Cipro®) and vancomycin in patients who report an allergy to penicillin. The
antibiotics are given prior to surgery to prevent infection. In non-allergic patients,
cephalosporins and other less potent classes of antibiotics are typically used.
“Many surgeons prescribe ciprofloxacin or vancomycin in patients with penicillin allergy
because some studies have shown that these patients may also react to cephalosporins,” said
Lynn Watts, R.N., improvement coordinator, Delaware Surgery Center, who will accept the
award on behalf of the center. “More recent research indicates, however, that cephalosporins can
safely be given to some patients with penicillin allergies.”
The more potent antibiotics pose a higher risk of adverse reactions and can contribute to
the growing global problem of drug resistant infections. Before the program was initiated, seven
of 31 patients (23 percent) who were prescribed ciprofloxacin in a three-month period at the
Delaware Center developed adverse reactions to the drug.
With all antibiotics, there is the potential that patients will develop resistance to the
drugs. “Because of their potency against many types of infection, ciprofloxacin and vancomycin
are often considered drugs of last resort for infections that don’t respond to other antibiotics. We
don’t want patients to risk developing resistance to these drugs when many less potent drugs are
available for preventing postoperative infection,” Watts said.
In the program, patients were screened using a questionnaire based on an algorithm
published in scientific literature, which was modified significantly to meet the specific needs of
the Delaware center. Over 15 months, 300 patients with reported penicillin allergy were
screened, and 80 were randomly selected for analysis. Of the 80 patients studied, only 2 percent
received ciprofloxacin and 1 percent received vancomycin, a significant reduction in the center’s
use of these drugs. The other patients received cephalosporins or other less potent antibiotics.
There were no adverse reactions in any of the patients.
“The program also significantly reduced our costs,” Watts said. During the study period,
the center realized $2,000 in savings by decreasing use of the more potent – and more expensive
The AAAHC Institute for Quality Improvement
(AAAHC Institute) is among the few
organizations to provide ambulatory care providers with the opportunities for benchmarking on a
national level. The Accreditation Association established the AAAHC Institute in 1999 to
provide ambulatory health care organizations opportunities to participate in quality improvement
and performance measurement studies and educational programs. To date, the AAAHC Institute
has conducted and published more than 50 performance measurement studies and has convened
annual national educational forums on quality improvement in ambulatory health care.
Involvement in clinical performance measurement is a signal to patients, government agencies,
professional liability insurers, and third-party payers, that an ambulatory health organization is
committed to continually improving the care it provides to its patients.
The Accreditation Association for Ambulatory Health Care
Association), founded in 1979, is celebrating its 30th anniversary as the leader in ambulatory
health care accreditation, with more than 4,500 organizations accredited nationwide. The
AAAHC accredits a variety of ambulatory health care organizations, including ambulatory
surgery centers, office-based surgery centers, college student health centers, managed care
organizations, military health care clinics, and large medical and dental practices. The
Accreditation Association serves as an advocate for the provision of high-quality health care
through the development of nationally recognized standards and through its survey and
accreditation programs. AAAHC accreditation is recognized as a symbol of quality by third-
party payers, medical organizations, liability insurance companies, state and federal agencies and
*Schools participating in the NCDP partnership are
Baruch College of the City University of New York
Case Western Reserve University, Cleveland, Ohio
Columbia University, New York City, N.Y.
Evergreen State University, Olympia, Wash.
Rensselaer Polytechnic Institute, Troy, N.Y.
Sarah Lawrence College, Bronxville, N.Y.
School of the Art Institute of Chicago, Ill.
Skidmore College, Saratoga Springs, N.Y.
FSCO A02–000307 BETWEEN: SAVITHIRI SIVANANTHAN Applicant STATE FARM MUTUAL AUTOMOBILE INSURANCE COMPANY REASONS FOR DECISION January 20, 21, 22, 23 and March 28, 2003, at the offices ofthe Financial Services Commission of Ontario in Toronto. Written submissions were received on April 24, 2003. Appearances: Moira Gracey for Mrs. SivananthanChristopher J. Schnarr for State Fa
For the third time in the last year I have been prevented from proceeding with radiotherapy treatment (RT) for my prostate cancer. After thirteen monthsof Zoladex (hormone treatment) my prostate has not reduced one iota in size; the gland remains the size of a cricket ball. My consultants say the glandis the biggest they have encountered. Normally Zoladex reduces the prostate by half in 13 weeks!